← Leaderboards
Ellen L Zakris
Tulane University Of Louisiana
$642,522
Attributed
$642,522
Total exposure
11
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $8.6K · FY2005–06$10K$7.5K$5K$2.5K$0
'05
'06
Funding mix
By agency
NIH$642,522 · 11
By mechanism
U01$611,016 · 1
M01$31,506 · 10
Top collaborators
No co-investigators on record.
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- William McKinnon$49,515
- Patricia S Braly$22,399
- Eugene A Woltering$73,643
- Russell Barrett Van Dyke$24,377,705
- Alan Marshall Miller$44,720
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationClinical ResearchHuman SubjectPatient Oriented ResearchNeoplasm /Cancer Radiation TherapyNeoplasm /Cancer ChemotherapyCombination Cancer TherapyClinical TrialsKaposi'S SarcomaLymphomaAids Related Neoplasm /CancerMedical Outreach /Case FindingPreneoplastic StateMagnetic Resonance ImagingCervix NeoplasmsNeoplasm /Cancer TherapyCancer PreventionAids TherapyComputed Axial TomographyCooperative StudyExperimental DesignsPaclitaxelTissue Resource /RegistryCombination Chemotherapy
Grant awards (17)
A PHASE III TRIAL OF CONCURRENT RADIATION AND CHEMOTHERAPY FOR HEAD/NECK CANCER$4,080
M01 · FY2006 · RR · contact PI
CHEMORADIOTHERAPY PLUS C225 (CETUXIMAB) FOR ADVANCED SQUAMOUS CELL CARCINOMA$2,137
M01 · FY2006 · RR · contact PI
POSTOPERATIVE PACLITAXEL FOLLOWED BY PACLITAXEL AND CISPLATIN IN HEAD/NECK CA$583
M01 · FY2006 · RR · contact PI
A PHASE III TRIAL OF CONCURRENT RADIATION AND CHEMOTHERAPY FOR HEAD/NECK CANCER$6,656
M01 · FY2005 · RR
STUDY OF NUTRITIONAL INTERVENTION FOR TREATMENT OF CANCER CACHEXIA USING JUVEN$1,035
M01 · FY2005 · RR
POSTOPERATIVE PACLITAXEL FOLLOWED BY PACLITAXEL AND CISPLATIN IN HEAD/NECK CA$887
M01 · FY2005 · RR
Phase II Trial of Preoperative Combined Modality Therapy$9,013
M01 · FY2004 · RR
Postoperative Paclitaxel &Paclitaxel and Cisplatin$2,651
M01 · FY2004 · RR
Paclitaxel Vs Liposomal Doxorubicin for Kaposi's Sarcoma$2,166
M01 · FY2004 · RR
Trial to Assess the Effect of Erythropoietin on Anemics$1,944
M01 · FY2004 · RR
A Phase III Trial of Concurrent Radiation &Chemotherapy$354
M01 · FY2004 · RR
TULANE AIDS-ASSOCIATED MALIGNANCY CONSORTIUM$158,510
U01 · FY2003 · CA
TULANE AIDS-ASSOCIATED MALIGNANCY CONSORTIUM$154,826
U01 · FY2002 · CA
TULANE AIDS-ASSOCIATED MALIGNANCY CONSORTIUM$151,039
U01 · FY2001 · CA
IRRADIATION + CISPLATIN/TAXOL FOR ENDOMETRIAL CANCER$0
M01 · FY2001 · RR
TULANE AIDS-ASSOCIATED MALIGNANCY CONSORTIUM$146,641
U01 · FY2000 · CA
IRRADIATION + CISPLATIN/TAXOL FOR ENDOMETRIAL CANCER$0
M01 · FY2000 · RR